Supernus Pharmaceuticals (SUPN) Wells Fargo 21st Annual Healthcare Conference summary

Strategic growth and portfolio development

• Focused on R&D and external growth through M&A, resulting in a robust portfolio of 12 marketed products developed internally and via acquisitions.

• Successfully managed loss of exclusivity (LOE) for key products by introducing new internally developed and acquired products, maintaining revenue and profitability.

• CNS remains the core therapeutic area, with expansion into women's health via postpartum depression assets.

• Revenue guidance for the year raised to $860M-$890M, driven by strong growth in flagship and new products.

• Four growth products contributed to over 50% revenue increase, with Qelbree leading as the flagship.

ADHD franchise and Qelbree performance

• ADHD market has accelerated post-pandemic, with adult segment growing faster than pediatric.

• Qelbree offers a non-stimulant alternative, providing rapid onset and addressing both pediatric and adult needs.

• Adult prescriptions for Qelbree are rising, with 40% using combination therapy before tapering off stimulants.

• Qelbree annualizing at $360M, with significant room for growth in both adult and pediatric segments due to low current market penetration.

• Innovation and new mechanisms in ADHD are welcomed, with ongoing internal development of new stimulants.

Parkinson’s and movement disorder franchise

• ONAPGO launch progressing well post-supply constraints, with guidance set at $55M-$70M for 2026 and peak sales estimated at $200M-$300M.

• Patient profile for ONAPGO is evolving, with potential for broader use as seen in Europe.

• Broader franchise includes GOCOVRI, APOKYN, MYOBLOC, and XADAGO, covering various stages and needs in Parkinson’s disease.

• GOCOVRI is the only product approved for both OFF episodes and dyskinesia, while APOKYN provides rapid relief for OFF episodes.

• ONAPGO infusion device targets advanced patients, with potential for earlier-stage adoption.